Stocks and Investing Stocks and Investing
Fri, November 11, 2022
Thu, November 10, 2022

Matthew Biegler Maintained (ZNTL) at Buy with Decreased Target to $50 on, Nov 10th, 2022


Published on 2024-10-28 00:05:43 - WOPRAI, Matthew Biegler
  Print publication without navigation


Matthew Biegler of Oppenheimer, Maintained "Zentalis Pharmaceuticals, Inc." (ZNTL) at Buy with Decreased Target from $80 to $50 on, Nov 10th, 2022.

Matthew has made no other calls on ZNTL in the last 4 months.



There are 4 other peers that have a rating on ZNTL. Out of the 4 peers that are also analyzing ZNTL, 0 agree with Matthew's Rating of Hold.



These are the ratings of the 4 analyists that currently disagree with Matthew


  • Bradley Canino of "Stifel" Maintained at Strong Buy with Decreased Target to $58 on, Wednesday, November 9th, 2022
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $60 on, Thursday, August 11th, 2022
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $55 on, Wednesday, August 10th, 2022
  • Tyler Van Buren of "Cowen & Co." Initiated at Buy on, Tuesday, July 12th, 2022

Contributing Sources